Public dataset
Recorded enzyme and transporter findings by polarity
Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.
What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
- Public rows
- 8,404
- Generated
- Schema version
- 1.3.0
Coverage
What this run contains
- Medicine–counterparty–role groups
- 8,404
- Source sentence records
- 20,358
- Asserted sentences
- 4,700
- Denied sentences
- 7,494
- Polarity not recorded
- 8,164
- Medicines represented
- 755
- Counterparties represented
- 36
- Corpus records considered
- 9,855
- All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
- inducer groups
- 617
- inhibitor groups
- 3,131
- not_recorded groups
- 3,074
- substrate groups
- 1,582
Method
How the rows were made
- A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
- A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
- Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
- Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
- The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.
Limits
Read these before using a row
- A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
- This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
- ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
- A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
- 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
- Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
- 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
- 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
- The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
- The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
- A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
- Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.
Provenance
Source examples
Abacavir · CYP3A4 inhibitor
2 asserted · 2 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.
Abacavir · BCRP substrate
0 asserted · 4 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.
Abacavir · CYP2C9 not_recorded
0 asserted · 0 denied · 2 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).
Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| medicineName | string | Recorded medicine name; not normalized for display style. |
| counterparty | string | The exact recorded counterparty spelling. |
| role | string | SUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role. |
| assertedCount | number | Sentence records whose polarity is ASSERTED. |
| deniedCount | number | Sentence records whose polarity is NEGATED. |
| polarityNotRecordedCount | number | Sentence records for which the parser did not settle assertion or denial. |
| sentences | sentence[] | Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated. |
Reader
Search and filter the rows
Showing 3,171–3,180 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 3171
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP1A2
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
Projected row 3172
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2B6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Drugs Metabolized by CYP2B6 (Bupropion) An open-label, randomized, two-period crossover study in 28 healthy women evaluated the effect of flibanserin on the pharmacokinetics of bupropion.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Drugs Metabolized by CYP2B6 (Bupropion) An open-label, randomized, two-period crossover study in 28 healthy women evaluated the effect of flibanserin on the pharmacokinetics of bupropion.
Projected row 3173
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2C19
- Role
- INHIBITOR
- Asserted sentences
- 3
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Moderate CYP3A4/Moderate CYP2C9/Strong CYP2C19 Inhibitor (Fluconazole) In a study of 15 healthy female subjects, a fluconazole 400 mg loading dose followed by 200 mg administered once daily for 5 days increased flibanserin 100 mg single dose exposure (AUC 0-inf ) 7-fold and Cmax 2.2-fold compared to flibanserin 100 mg alone.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Moderate CYP3A4/Moderate CYP2C9/Strong CYP2C19 Inhibitor (Fluconazole) In a study of 15 healthy female subjects, a fluconazole 400 mg loading dose followed by 200 mg administered once daily for 5 days increased flibanserin 100 mg single dose exposure (AUC 0-inf ) 7-fold and Cmax 2.2-fold compared to flibanserin 100 mg alone.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
CYP2C19 Poor Metabolizers A study comparing flibanserin exposure in CYP2C19 poor metabolizers to CYP2C19 extensive metabolizers was conducted in lieu of a drug interaction study with ADDYI and a strong CYP2C19 inhibitor.
Projected row 3174
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2C19
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 6
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Elimination Metabolism Flibanserin is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Elimination Metabolism Flibanserin is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
In 9 women who were poor metabolizers of CYP2C19, Cmax and AUC 0-inf of flibanserin 100 mg once daily increased 1.5-fold (1.1-2.1) and 1.3-fold (0.9-2.1), compared to exposures among 8 extensive metabolizers of CYP2C19.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Flibanserin half-life was increased from 11.1 hours in the extensive metabolizers of CYP2C19 to 13.5 hours in the poor metabolizers of CYP2C19 [see Adverse Reactions (6.1) and Use in Specific Populations (8.7) ] .
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
The frequencies of poor metabolizers of CYP2C19 are approximately 2–5% among Caucasians and Africans and approximately 2–15% among Asians.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
In 8 women who were poor metabolizers of CYP2C9, Cmax and AUC 0-inf of flibanserin 100 mg once daily decreased 23% and 18%, compared to exposures among 8 extensive metabolizers of CYP2C9 . 12.5 Pharmacogenomics Patients who are poor metabolizers of CYP2D6, CYP2C9 or CYP2C19 are deficient in CYP2D6, CYP2C9 or CYP2C19 enzyme activity, respectively.
Projected row 3175
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2C8
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
Projected row 3176
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2C9
- Role
- INHIBITOR
- Asserted sentences
- 3
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Moderate CYP3A4/Moderate CYP2C9/Strong CYP2C19 Inhibitor (Fluconazole) In a study of 15 healthy female subjects, a fluconazole 400 mg loading dose followed by 200 mg administered once daily for 5 days increased flibanserin 100 mg single dose exposure (AUC 0-inf ) 7-fold and Cmax 2.2-fold compared to flibanserin 100 mg alone.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Moderate CYP3A4/Moderate CYP2C9/Strong CYP2C19 Inhibitor (Fluconazole) In a study of 15 healthy female subjects, a fluconazole 400 mg loading dose followed by 200 mg administered once daily for 5 days increased flibanserin 100 mg single dose exposure (AUC 0-inf ) 7-fold and Cmax 2.2-fold compared to flibanserin 100 mg alone.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
CYP2C9 Poor Metabolizers A study comparing flibanserin exposure in CYP2C9 poor metabolizers to CYP2C9 extensive metabolizers was conducted in lieu of a drug interaction study with ADDYI and a strong CYP2C9 inhibitor.
Projected row 3177
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2C9
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
In 8 women who were poor metabolizers of CYP2C9, Cmax and AUC 0-inf of flibanserin 100 mg once daily decreased 23% and 18%, compared to exposures among 8 extensive metabolizers of CYP2C9 . 12.5 Pharmacogenomics Patients who are poor metabolizers of CYP2D6, CYP2C9 or CYP2C19 are deficient in CYP2D6, CYP2C9 or CYP2C19 enzyme activity, respectively.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
In 8 women who were poor metabolizers of CYP2C9, Cmax and AUC 0-inf of flibanserin 100 mg once daily decreased 23% and 18%, compared to exposures among 8 extensive metabolizers of CYP2C9 .
Projected row 3178
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2D6
- Role
- INHIBITOR
- Asserted sentences
- 3
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Strong CYP2D6 Inhibitor (Paroxetine) Paroxetine is a strong CYP2D6 inhibitor.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Strong CYP2D6 Inhibitor (Paroxetine) Paroxetine is a strong CYP2D6 inhibitor.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
CYP2D6 Poor Metabolizers A study comparing flibanserin exposure in CYP2D6 poor metabolizers to CYP2D6 extensive metabolizers was conducted in addition to a drug interaction study with paroxetine, a strong CYP2D6 inhibitor.
Projected row 3179
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP2D6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
In 12 poor metabolizers of CYP2D6, steady state Cmax and AUC of flibanserin 50 mg twice daily was decreased by 4% and increased by 18%, respectively, compared to exposures among 19 extensive metabolizers, intermediate metabolizers and ultra rapid metabolizers of CYP2D6 .
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
In 8 women who were poor metabolizers of CYP2C9, Cmax and AUC 0-inf of flibanserin 100 mg once daily decreased 23% and 18%, compared to exposures among 8 extensive metabolizers of CYP2C9 . 12.5 Pharmacogenomics Patients who are poor metabolizers of CYP2D6, CYP2C9 or CYP2C19 are deficient in CYP2D6, CYP2C9 or CYP2C19 enzyme activity, respectively.
Projected row 3180
- Medicine slug
- flibanserin
- Medicine name
- Flibanserin
- Enzyme or transporter
- CYP3A4
- Role
- INDUCER
- Asserted sentences
- 4
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Drugs that Decrease Flibanserin Exposure Strong CYP3A4 Inducer (Rifampin) In a study of 24 healthy female subjects, rifampin 600 mg given once daily for 7 days prior to administration of 100 mg flibanserin significantly decreased flibanserin exposure by 95% [see Drug Interactions (7) ].
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Moderate CYP3A4 Inducer (Etravirine) Steady state etravirine, a moderate CYP3A4 inducer, decreased flibanserin exposures by approximately 21% [see Drug Interactions (7) ] .
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Drugs that Decrease Flibanserin Exposure Strong CYP3A4 Inducer (Rifampin) In a study of 24 healthy female subjects, rifampin 600 mg given once daily for 7 days prior to administration of 100 mg flibanserin significantly decreased flibanserin exposure by 95% [see Drug Interactions (7) ].
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3819daf3-e935-2c53-c527-e1d57922f394 (opens source in a new tab)
Flibanserin label
Version not recorded · Effective date not recorded
Moderate CYP3A4 Inducer (Etravirine) Steady state etravirine, a moderate CYP3A4 inducer, decreased flibanserin exposures by approximately 21% [see Drug Interactions (7) ] .
Access
Query or download the projection
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=3170Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- role
- Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
- counterparty
- Exact recorded counterparty spelling.
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.